MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
4.690
-0.330
-6.57%
After Hours: 4.780 +0.09 +1.92% 19:14 01/02 EST
OPEN
5.10
PREV CLOSE
5.02
HIGH
5.16
LOW
4.650
VOLUME
2.10M
TURNOVER
--
52 WEEK HIGH
5.66
52 WEEK LOW
1.285
MARKET CAP
681.27M
P/E (TTM)
-3.3763
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ANNX last week (1222-1226)?
Weekly Report · 12/29/2025 10:25
Vizsla, Coty, Kalaris, Annexon, Brown & Brown Trending
TipRanks · 12/27/2025 09:01
Annexon Initiated at Buy by Chardan Capital
Dow Jones · 12/23/2025 14:02
Annexon Price Target Announced at $16.00/Share by Chardan Capital
Dow Jones · 12/23/2025 14:02
Chardan Capital Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $16
Benzinga · 12/23/2025 13:52
Annexon initiated with a Buy at Chardan
TipRanks · 12/23/2025 09:35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF) and Annexon Biosciences (ANNX)
TipRanks · 12/23/2025 09:30
Weekly Report: what happened at ANNX last week (1215-1219)?
Weekly Report · 12/22/2025 10:24
More
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.